TCRX
$1.09
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Recent News
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.25% and +94.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?